Drug makers get green light to fund your copays—and raise prices

What it does

This bill allows financial assistance from nonprofits and drug manufacturers to count toward patients' deductibles, copayments, and out-of-pocket limits under health insurance plans. Starting in 2026, when a patient receives copay assistance (e.g., a manufacturer pays $100 of a $150 copay), that $100 now counts as if the patient paid it themselves, reducing their remaining out-of-pocket obligation. The bill also protects high-deductible health plans from losing tax-advantaged status when they accept manufacturer copay assistance.

Why we flagged it

The bill's operative mechanism is to legitimize and incentivize manufacturer-funded copay assistance by making it count toward cost-sharing thresholds. While framed as patient relief, the primary beneficiary is the pharmaceutical industry, which gains a regulatory safe harbor to use copay programs as a pricing and market-capture tool without triggering high-deductible plan disqualification.

What the text implies

• Copay assistance funded by manufacturers becomes a de facto price subsidy that obscures true drug costs from patients and insurers, potentially enabling higher list prices without visible consumer resistance.
• High-deductible health plan (HDHP) safe harbor removes a regulatory brake on manufacturer copay programs; previously, excessive copay assistance could disqualify a plan from HDHP tax treatment. This amendment eliminates that constraint.
• Insurers and employers may face pressure to accept manufacturer copay assistance as a cost-control measure, effectively outsourcing deductible satisfaction to pharmaceutical companies and reducing insurers' negotiating leverage on drug pricing.
• Patients without access to manufacturer copay programs (generic drugs, older medications, drugs from smaller manufacturers) face relative disadvantage; their out-of-pocket costs do not benefit from the same assistance framework.
• The rule of construction preserves utilization management tools (prior authorization, step therapy), meaning manufacturers can use copay assistance to bypass these cost-control mechanisms, paying patients' copays while the insurer's gatekeeping is circumvented.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Patients with access to copay assistance programs will see immediate out-of-pocket relief and faster progress toward deductible satisfaction. However, the bill creates a structural incentive for drug manufacturers to fund copay assistance as a marketing tool rather than a genuine affordability measure, potentially inflating drug prices industry-wide and shifting costs to insurers, employers, and uninsured patients. The net public benefit depends on whether copay assistance expands access or beco

Who stands to gain

• pharmaceutical manufacturers
• specialty drug companies
• health insurers (short-term cost transfer)
• nonprofit copay assistance programs (if funded by manufacturers)

Named in the bill

Public Health Service Act (42 U.S.C. 300gg–15), Patient Protection and Affordable Care Act (PPACA), Internal Revenue Code Section 223 (high-deductible health plans), Pharmaceutical manufacturers, Nonprofit organizations, Health insurers, Employers

Where it stands

67 cosponsors: 54 Democrats, 13 Republicans.

• Dec 4, 2025 — Introduced · Congress.gov: “Introduced in House”
• Dec 4, 2025 — Referred to House Committee on Ways and Means and House Committee on Energy and Commerce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

14 lobbying clients named this bill on 18 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $21,870,000 in lobbying spend. A filing names 9 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 94% of bills with at least one filing.

Thomas Kean, the sponsor, reported $1,220,477 in PAC receipts in the 2026 cycle.

• Pharmaceutical Research and Manufacturers of America — $15,770,000 on 2 filings
• Vertex Pharmaceuticals Incorporated — $2,310,000 on 2 filings
• Sanofi Us Services Inc — $920,000 on 1 filing
• Gsk (fka Glaxosmithkline Inc.) — $890,000 on 1 filing
• Ucb, Inc. — $710,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.